Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

doi:10.1200/JCO.2008.18.8391

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2009

Baselga José, Semiglazov Vladimir, van Dam Peter, Manikhas Alexey, Bellet Meritxell, Mayordomo José, Campone Mario, Kubista Ernst, Greil Richard, Bianchi Giulia, Steinseifer Jutta, Molloy Betty, Tokaji Erika, Gardner Humphrey, Phillips Penny, Stumm Michael, Lane Heidi A, Dixon J Michael, Jonat Walter, Rugo Hope S

Abstract excerpt

PURPOSE: Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001). PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Everolimus

Share to Ki-67 Antigen

Share to Neoadjuvant Therapy

Share to Ribosomal Protein S6 Kinases

Share to Sirolimus

Share to Triazoles

Source

Open in PubMed

Identifiers

PMID: 19380449
DOI: 10.1200/JCO.2008.18.8391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.PMID 19380449Read ↗

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoSemantic proximity Read ↗

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.Semantic proximity Read ↗

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.Semantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.Semantic proximity Read ↗

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialSemantic proximity Read ↗

A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-positive and Her2-negative Breast Cancer.Semantic proximity Read ↗

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.Semantic proximity Read ↗

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.Semantic proximity Read ↗

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.